Published in AIDS on March 10, 2000
Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microbiol Rev (2002) 3.27
The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev (2000) 1.15
A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend (2001) 0.98
Prediction of abacavir resistance from genotypic data: impact of zidovudine and lamivudine resistance in vitro and in vivo. Antimicrob Agents Chemother (2002) 0.90
Abacavir/lamivudine combination in the treatment of HIV: a review. Ther Clin Risk Manag (2010) 0.79
Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J Clin Microbiol (1993) 45.22
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods (1988) 7.74
Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature (1990) 5.70
(E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent. Proc Natl Acad Sci U S A (1979) 5.28
A conformational and structure-activity relationship study of cytotoxic 3,5-bis(arylidene)-4-piperidones and related N-acryloyl analogues. J Med Chem (2001) 4.82
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med (1998) 4.77
Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis (1980) 4.67
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci (2001) 4.12
Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol (1997) 4.08
Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med (1997) 3.62
Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines. Antiviral Res (1987) 3.46
The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med (1996) 3.30
Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero). J Virol (1968) 3.29
Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one. Pharm Acta Helv (1999) 3.24
A novel selective broad-spectrum anti-DNA virus agent. Nature (1986) 2.98
Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol (2002) 2.86
Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1988) 2.82
Macrophage tropism of human immunodeficiency virus type 1 isolates from brain and lymphoid tissues predicts neurotropism independent of coreceptor specificity. J Virol (2001) 2.79
Postnatal transmission of HIV from mother to child. Lancet (1987) 2.60
Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature (1995) 2.56
Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother (1993) 2.52
Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med (2000) 2.49
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Angiogenesis: regulators and clinical applications. Biochem Pharmacol (2001) 2.47
An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives. Proc Natl Acad Sci U S A (1991) 2.37
Letter: Keratoconjunctivitis caused by Adenovirus Type 19. Br Med J (1974) 2.36
Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet (2004) 2.33
Synthesis and antimicrobial activity of Schiff and Mannich bases of isatin and its derivatives with pyrimidine. Farmaco (1999) 2.31
Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Res (1987) 2.27
Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother (1994) 2.26
Ribavirin antagonizes inhibitory effects of pyrimidine 2',3'-dideoxynucleosides but enhances inhibitory effects of purine 2',3'-dideoxynucleosides on replication of human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1987) 2.24
Differential distribution of hepatitis B surface antigen and hepatitis B core antigen in the liver of hepatitis B patients. Gastroenterology (1976) 2.17
Antiviral effects of plasma and milk proteins: lactoferrin shows potent activity against both human immunodeficiency virus and human cytomegalovirus replication in vitro. J Infect Dis (1995) 2.16
Phosphonylmethoxyethyl purine derivatives, a new class of anti-human immunodeficiency virus agents. Antimicrob Agents Chemother (1988) 2.16
Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS (1996) 2.14
Incomplete overlapping of biological, clinical, and environmental information in molecular epidemiological studies: a variety of causes and a cascade of consequences. J Epidemiol Community Health (2002) 2.13
Sensitive and rapid assay on MT-4 cells for detection of antiviral compounds against the AIDS virus. J Virol Methods (1987) 2.10
Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc Natl Acad Sci U S A (1991) 2.08
Biochemical genetics of Neurospora crassa conidial germination. Bacteriol Rev (1976) 2.07
Evaluation of six enzyme immunoassays for antibody against human immunodeficiency virus. Lancet (1986) 2.04
Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS (1999) 2.00
On the mechanism of selective inhibition of herpesvirus replication by (E)-5-(2-bromovinyl)-2'-deoxyuridine. Proc Natl Acad Sci U S A (1981) 2.00
Differential affinities of 5-(2-halogenovinyl)-2'-deoxyuridines for deoxythymidine kinases of various origins. Mol Pharmacol (1981) 1.94
[Prevalence of antibodies against hepatitis C virus in a sample of homosexual males]. Med Clin (Barc) (1993) 1.94
HIV-1-specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology (1993) 1.92
Synthesis and antiviral activity evaluation of some aminoadamantane derivatives. J Med Chem (1994) 1.91
HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection. AIDS (2001) 1.90
Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res (1997) 1.90
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci U S A (1992) 1.89
Sulfated polysaccharides extracted from sea algae as potential antiviral drugs. Gen Pharmacol (1997) 1.89
Differential patterns of intracellular metabolism of 2',3'-didehydro-2',3'-dideoxythymidine and 3'-azido-2',3'-dideoxythymidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem (1989) 1.89
Phenotypic assays and sequencing are less sensitive than point mutation assays for detection of resistance in mixed HIV-1 genotypic populations. J Acquir Immune Defic Syndr (1999) 1.88
Sulfated polymers inhibit the interaction of human cytomegalovirus with cell surface heparan sulfate. Virology (1992) 1.87
The prevalence of antibody to hepatitis A antigen in various parts of the world: a pilot study. Am J Epidemiol (1977) 1.86
Nonnucleoside human cytomegalovirus inhibitors: synthesis and antiviral evaluation of (chlorophenylmethyl)benzothiadiazine dioxide derivatives. J Med Chem (2000) 1.86
The IgM antibody response in rubella during pregnancy. J Med Microbiol (1971) 1.85
Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Lett (1979) 1.84
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Synthesis and antiviral properties of 5-vinylpyrimidine nucleoside analogs. Pharmacol Ther (1984) 1.82
CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. J Virol (1998) 1.81
Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS (2001) 1.81
Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol (1998) 1.81
HIV-associated hematologic disorders are correlated with plasma viral load and improve under highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.80
Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother (1977) 1.79
Measuring passionate love in intimate relationships. J Adolesc (1986) 1.79